| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| Alpha-fetoprotein | Human Alpha-fetoprotein, His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 50ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| TAEST-1901 | TAEST-1901 | Phase 2 Clinical | Xiangxue Life Science Technology (Guangdong) Co Ltd | Liver Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| JWATM-203 | JWATM-203; JWATM203 | Phase 2 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Carcinoma, Hepatocellular | 詳細 |
| SynOV1.1 | SynOV1.1 | Phase 2 Clinical | Beijing Syngentech Co Ltd | Carcinoma, Hepatocellular; Solid tumours | 詳細 |
| ET140203 | Phase 2 Clinical | Eureka Therapeutics Inc | Carcinoma, Hepatocellular; Hepatoblastoma; Liver Neoplasms | 詳細 | |
| CPU-118 | CPU-118 | Phase 2 Clinical | China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd | Liver Neoplasms; Neoplasms; Solid tumours | 詳細 |
| Alpha fetoprotein targeted T-cell therapy (Adaptimmune) | AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T | Phase 1 Clinical | Adaptimmune Llc | Carcinoma, Hepatocellular | 詳細 |